Innovative therapeutics

Investors

BioMarin to Webcast Presentation at the Morgan Stanely Small Cap Executive Conference
Jun 13, 2005
PRNewswire-FirstCall
NOVATO, Calif.

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer and Director of BioMarin, will present a company update at the Morgan Stanely Small Cap Executive Conference on Wednesday, June 15, 2005 at 8:45 a.m. ET.

The webcast will be available on the investor section of the BioMarin website, www.BMRN.com. If you are unable to listen to the live webcast, it will be archived on the site for at least one week following the presentation. To access the replay, go to the investor section of the site.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of three approved products and multiple product and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution) for severe asthma. Investigational product candidates include Phenoptin(TM) (sapropterin hydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

NOTE: Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.

   Contacts:
   Investors                               Media
   Joshua A. Grass                         Susan Ferris
   BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
   415-506-6777                            415-506-6701

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: investors, Joshua A. Grass, +1-415-506-6777, or media,
Susan Ferris, +1-415-506-6701, both of BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information